Skip to main content
Menu
Home
Partnered Assets
Latest News
Team
Close Search
Developing novel immunotherapies for autoimmune disease and cancer
ImmuNext's anti-CD40L antagonist enters THIRD Sanofi-led Phase 2 trial
NCT05039840
Learn about our other immunotherapy assets.
Close Menu
Home
Partnered Assets
Latest News
Team